Precisely Empowers Customers to Unlock Business Value from ESG Reporting with Trusted Data
25.4.2023 16:00:00 EEST | Business Wire | Press release
Precisely, the global leader in data integrity, today announced that it is partnering with customers worldwide to build trust in data for effective ESG reporting processes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230425005089/en/
(Photo: Business Wire)
The powerful combination of the Precisely Data Integrity Suite and expert strategic services allows customers to easily combine multiple sources of ESG data for real-time insights, improve confidence in the data quality of ESG metrics, ensure data governance while maintaining compliance with industry regulations, and enrich data with additional datasets to help reveal hidden context. Organizations leveraging data integrity in ESG reporting processes see tangible results such as:
- Improved combination and alignment of fundamental ESG data with datasets that add context and meaning, such as geographic, demographic, or economic data
- Enhanced capture and organization of ESG data from multiple sources, breaking down siloes and making it available in real-time
- More robust standards and controls that ensure ESG data is accurate, consistent, and fit for purpose across operational and analytical systems
- Better governance of data storage, access, use, and exchange between systems while maintaining privacy, security, and compliance with complex regulations
Organizations are increasingly recognizing a need to overhaul ESG reporting, with 41% of finance leaders recently admitting that their current processes would not stand up to the scrutiny of basic assurance standards. With new research from IDC showing that data management concerns are the leading driver for ESG investment, there is no better time for businesses to leverage trusted data to drive accurate reporting processes, achieve meaningful outcomes, and unlock true business value from ESG-focused initiatives.
Vontobel, a globally active investment firm with Swiss roots, have ensured they are ahead of the curve by partnering with Precisely to focus on data integrity. The firm not only ensures that all investment strategies are ESG compliant, but goes one step further by setting its own additional sustainable investment criteria to ensure the best possible investment solutions for clients. The optimization of the ESG data processes for the portfolio valuation is crucial - this includes comprehensive data analysis as well as quality and completeness checks.
"Collecting data is nothing new for investment companies, but the challenge now is how to cater to the new volumes of data needed for meaningful ESG measurement and figure out which data elements are the most important,” said Christina Schack, Head of Data Platform at Vontobel. “Using proper tools to automate data quality checks in the data cleansing process is very important to handle and control the immense amount of ESG data. Implementing automated checks and ingestion of the data has greatly helped to reduce the manual work and achieve more accurate analysis for investment strategies."
Verisk Maplecroft, a leading global risk consultancy firm and specialist in sustainability, resilience, and ESG, also recognizes the importance of ESG reporting powered by accurate, consistent, and contextual data, particularly when combined with the right expertise:
“A more powerful way to approach ESG reporting is to hold it to the same standard of governance, processes, controls, assurance, and expertise that you would with your financial reporting,” said Mikkel Skougaard, Director of ESG Reporting and Strategy at Verisk Maplecroft. “Developing a data-driven ESG report is the most important factor, but this needs to be supported with high-quality contextual narrative in order to unlock maximum value.”
Skougaard will be in attendance at Precisely’s upcoming Data Integrity Summit, Trust ’23, joining Precisely CRO Pat McCarthy and Matthew Rusk, Head of Global Reporting Initiative (GRI) North America for a panel discussion on the importance of trusted data in harnessing true business value from ESG reporting, as well as advice for navigating evolving regulations and consumer expectations. The session takes place on May 17 with registration now open.
“Modern business practices demand complete transparency,” said McCarthy. “Investors, employees, and consumers alike want to know the companies they’re investing in, working for, and buying from not only meet their personal standards of ethics but are doing their part to create a better world. To stay compliant and achieve meaningful outcomes businesses need to prioritize data integrity in sustainability reporting and build trust in the data fueling their decisions.”
Learn more about the exciting speaker line up at Trust ’23 and register for your free place today.
About Precisely
Precisely is the global leader in data integrity, providing accuracy, consistency, and context in data for 12,000 customers in more than 100 countries, including 99 of the Fortune 100. Precisely’s data integration, data quality, data governance, location intelligence, and data enrichment products power better business decisions to create better outcomes. Learn more at www.precisely.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230425005089/en/
Contact information
Press Contact
Emma Forrest (Global)
press@precisely.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 09:10:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across systems, identify root causes, and execute actions within governed guardrails. iRun combines AI agents and human expertise to shift opera
Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
